Good morning, and welcome to Beauty Health Corp.'s 2022 Earnings Call. Please note that this event is being recorded. I’d like to turn the call over to Mr. Eduardo Rodriguez, Senior Director of M&A and Investor Relations. Please go ahead, sir.

Thank you, operator, and good morning, everyone. Thank you for joining Beauty Health Company's conference call to discuss the company's second quarter 2022 financial results, which were released this morning and can be found on our website at beautyhealth.com. Also available on our website is an investor presentation that will be referenced during this call. With me on the call today are Beauty Health's President and Chief Executive Officer, Andrew Stanleick; and Chief Financial Officer, Liyuan Woo. Before we get started, I would like to remind you of the company's safe harbor language. Management may make forward-looking statements, including guidance and underlying assumptions. Forward-looking statements are based on expectations that involve risks and uncertainties that could cause actual results to differ materially. For a further discussion of risks related to our business, see our filings with the SEC. This call will contain non-GAAP financial measures, such as adjusted gross margin and adjusted EBITDA. Reconciliation of these non-GAAP measures to the most comparable GAAP measures are included in the earnings release furnished to the SEC and available on our website. I will now turn the call over to Andrew Stanleick, President and Chief Executive Officer of Beauty Health Company.

Thank you, Eduardo. Good morning, everyone, and thank you for joining our second quarter earnings call. I'm excited to walk you through our spectacular second quarter performance as well as the strong progress we have made on our strategic master plan. Before we begin, I want to welcome Marla Beck, who joined our Board of Directors in June. As the founder of Bluemercury, Marla brings invaluable beauty industry, D2C and retail experience to our Board, and her positive impact is already felt. I also wish to extend a special thank you to the Beauty Health teams around the world. Since becoming the CEO six months ago, I've had the privilege of working with and meeting hundreds of you on my travels. I am constantly inspired by your passion, creativity, and commitment, and our excellent results are a testament to your amazing work. With that, I am pleased to announce that we achieved a record-breaking quarter, reaching sales above $100 million in a single quarter for the first time ever. You will see in our results that Beauty Health is firing on all cylinders with outstanding momentum across the business and a growing enthusiasm from our community for our efficacious, patent-protected Hydrafacial technology, which is fueling our growth. All of these extraordinary achievements come while we are still in the very early stages of disrupting this dynamic Beauty Health category. With our compelling competitive advantages, we believe we are just getting started on our growth journey. Turning to slide 5, we posted record high net sales of $103.5 million, representing nearly 56% growth year-on-year. We also delivered a strong adjusted EBITDA of $12.6 million, up nearly 11% year-over-year. It is our sixth consecutive quarter exceeding top-line expectations. Our sales growth is both impressive and accelerating, driven by record Hydrafacial system sales. We accelerated momentum in Q2 with total Hydrafacial delivery system sales growth of 85.4% year-over-year, setting another record of 2,738 total delivery systems sold. As part of this, the Syndeo rollout in the U.S. has been a tremendous success with 2,265 Syndeo's placed since launch in March. We are also seeing that consumer interest in Hydrafacial has never been higher, and I will come on to the growing momentum we are seeing here shortly. We are breaking records across our business, and the outlook has never been better. Based upon our performance and ongoing momentum, I am pleased to raise our 2022 net sales guidance to a range of $340 million to $350 million, and I reaffirm our $50 million adjusted EBITDA outlook, a growth of 53% versus 2021. The enthusiasm we see from our highly engaged community of providers validates raising our net sales guidance and our approach of investing to capture and fuel consumer demand is paying dividends. The expected operating leverage generated from our investments should drive profitable growth for the years to come as we work towards better profitability by the end of 2022 and continue the momentum towards historical levels in 2023. I look forward to providing more detail on our long-term growth ambitions at our Investor Day on the 15th of September. I will now turn to slide 6 to discuss the drivers of our performance in the quarter. In the Americas, we achieved growth of 76.6%, fueled by the launch of Syndeo. Having visited with hundreds of providers and consumers across the U.S., there is incredible enthusiasm for our new Syndeo delivery system, and we see it in our results. Our performance in EMEA is similarly exceptional. We registered growth of 56%. This was achieved by strong system sales and increased marketing activity across the region. We have been actively investing in the brand and participating in high-visibility tradeshows and events. The energy we are creating behind the brand is palpable. In line with our omni-channel approach to reach consumers where they live, work, and play, we are also rapidly expanding into new channels, including retail. We have just announced a permanent Hydrafacial presence at the iconic Galeries Lafayette Flagship on Boulevard Haussmann in Paris in partnership with Innerskin, who will be the exclusive aesthetic clinic provider in their state-of-the-art wellness gallery set to open in September. It is expected to be the largest space devoted to wellness in Europe. This complements the existing partnerships we have in other markets with Sephora, Ulta, Nordstrom, and John Lewis. Turning to APAC, the region is dynamic, and unsurprisingly, persistent COVID lockdowns in China impacted our results. APAC net sales declined 16.5%, partially offset by continued strength outside of China, especially in Australia. Liyuan and I recently had the privilege to visit our teams and providers across the APAC region, and the trip reinforced our belief in the large and untapped reservoir of growth that exists in APAC over the long-term. Looking ahead, the success we are seeing across the business and our growing momentum reinforce our confidence in the future. Hydrafacial is an unrivaled breakthrough technology. It creates efficacious results and it delivers a confidence-boosting experience that consumers love. We are at the nexus of a thriving market for beauty and health, pair this with a resilient upper middle-class consumer with a high affinity for beauty, and we have a powerful flywheel that gives us the conviction to continue reinvesting in growth for the future. Turning to slide 7, we continue to make strong progress against our 5-point master plan, and I will share an update on each point. First, we remain focused on placing new systems. The first phase of our Syndeo rollout in the U.S. was an outstanding success. Syndeo is a giant leap forward in skin health technology. Our customers are raving about the connected system and user experience. And on slide 8, you can see some of the feedback we have received. This is a first-of-its-kind digital experience in Beauty Health, and the buzz in the U.S. is creating growing excitement abroad. On slide 9, you will find our execution plan. The positive feedback we have with U.S. customers underscores the remarkable opportunity we see globally with Syndeo. Internationally, we plan to launch Syndeo in early 2023. In the meantime, we continue our remarkable expansion across existing and new channels in these important regions via our Elite system. Second, we continue to invest in our providers. We are proud to be one of the world's top trainers of estheticians. We view the unique relationship that we have created with this community via continuous education as a competitive advantage. This highly engaged community of providers and estheticians, the Hydrafacial nation, are our most powerful advocates. They inspire and educate consumers around the world every day about the benefits of Hydrafacial. Unleashing human magic by continued investment in education of our provider and esthetician community is a key pillar to driving increased utilization and brand awareness. Providers who go through our training become our most loyal, engaged, and enthusiastic brand evangelists. They typically record double-digit growth in consumable purchases and their second system sales happen 50% faster. One example of our investment in providers is EstiPalooza, an event we created to educate and celebrate our wonderful Hydrafacial community. You can get a flavor for EstiPalooza here on slide 10 and the enormous amount of content our highly engaged community creates for us on social channels. On slide 11, you will see examples of other investments we have made in our providers. We featured Hydrafacial at high-profile tradeshows in every region and have taken Hydrafacial on the road with our GLOWvolution tour, which we extended to Europe this year. Third, we continue to invest in initiatives to drive brand awareness. The biggest growth opportunity for Hydrafacial is to increase our brand awareness. We have a best-in-class product that is loved by those who try it, and we've made significant strides this quarter to expand our funnel by our investments in digital media, partnerships with influencers and key opinion leaders such as Dr. Paul Nassif, and the expanded GLOWvolution tour. As you see on slide 12, more consumers are seeking information about Hydrafacial, with Google Search activity reaching an all-time high in Q2, up 30% year-over-year. We also generated record levels of earned media value this quarter. As we look ahead to Q4, we will launch an incredible Hydrafacial booster partnership with JLo Beauty by Jennifer Lopez. We are excited about the positive impact this will have on brand awareness, given the strength of JLo's global community of loyal fans. We are also driving brand awareness by expanding touchpoints with consumers. As you know, late last year, we beta tested an at-home device called Glow & Go. Through this test, we gained valuable insights that validated our belief in the potential opportunity of a take-home product from Hydrafacial. We will refine the current concepts with the insights garnered from this test and launch a take-home product at a future date. In the meantime, we remain laser-focused on continuing the successful global rollout of Syndeo. As a reminder, revenue from Glow & Go was never part of our 2022 guidance. Fourth, we continue to build our global infrastructure. Slide 13 illustrates some of the initiatives we advanced during the quarter. The international integration of our ERP system is on track to be completed by the end of 2022, and our global efforts in hiring talent, network automation, and brand building are well underway. We expect these initiatives will generate operating leverage in the years to come. And fifth, M&A. Looking forward, we see a great opportunity in front of us to use M&A in a strategic and disciplined manner. During the quarter, we invested $2 million in a personalized skin care company. It provides a great opportunity for us to test and learn in this rapidly growing space of personalization that leverages data and technology. We continue to be laser-focused on delivering strategic M&A. On the left slide of 14, you will see the acquisition criteria we have previously laid out. On the right is our playbook for building our Beauty Health platform. As you know, we continue to be prudent in our approach and remain focused on digestible, accreted, differentiated products that leverage our unique community. Before I turn it to Liyuan, I want to reiterate how incredibly proud I am of what our team has achieved in the first half of the year. Consumer interest and our confidence-boosting experience has never been higher. We attract a resilient, highly desirable consumer and continue to see strong demand. The enthusiasm of our team is electrifying, and we are eager to sustain our profitable hyper-growth trajectory. We have a tremendous opportunity ahead of us. I will now turn the call to Liyuan for a more detailed discussion of our second quarter performance.

Thank you, Andrew, and thank you, everyone, for joining the call. To reiterate Andrew's comments, I'd like to thank our dedicated employees and partners around the globe for delivering our best quarter ever. This marks the sixth consecutive quarter of exceeding top-line expectations. Over the past few months, Andrew and I traveled throughout the U.S. and APAC, meeting our teams and providers, I could not be more excited about the passion and excitement shared amongst our community. Today, I'll walk you through our second quarter results, catch on our balance sheet, and discuss our full year guidance in a bit more detail. Turning to our net sales results on slide 16; we delivered record second quarter net sales of $103.5 million, up 55.7% year-over-year despite softness in APAC from the COVID lockdowns in China. Strong global demand for delivery systems and consumables drove the outperformance. On the left, you will see Delivery Systems sales growth was 85.4% year-over-year. We shipped 2,738 systems, of which 1,203 were trade-ups, accounting for approximately $23.3 million in incremental net sales this quarter. You will recall from last quarter that 742 of the trade-up systems sold in Q2 were rollovers from orders placed in Q1. Excluding the net sales generated from trade-up, Delivery Systems growth was 21.5% year-over-year, a testament to the continued demand for our products. Turning to Consumables; we delivered strong sales growth of 22.8% year-over-year for a total of $38.8 million. As a reminder, we include an initial 2- to 3-month supply of consumables with each new system sold and with each Syndeo trade-up sold. This contributes to a lag in the pull-through of consumables revenue, a trend we expect to continue as we rapidly expand our install base and launch Syndeo internationally in early 2023. We also instituted our annual price increase in mid-May. Consistent with prior price increases, there has been no material impact to reordering patterns. Moving to the regional performance on the right; Americas net sales grew 76.6% year-over-year or 22% excluding trade-ups, driven by the outstanding performance of new Syndeo placements. In EMEA, we saw sales growth of 56% year-over-year, driven by high conversion on our marketing activations in the region. The results are a validation of our test-and-learn approach, where we experiment with driving consumer demand in various ways, including targeted tradeshows, hosting experience center events, and driving retail-related activations. We expect that this buzz generated as a result of these initiatives will fuel growth for the rest of 2022. As a result of the COVID lockdowns in China, net sales in APAC declined 16.5%. Despite this, we remain confident in our view on the APAC market opportunities even more so after the productive and inspiring visits we had to the region. Our original guidance anticipated lockdown in China in the first half of this year, and our guidance models are gradually opening in the second half. We ended the quarter with an install base of 22,929 delivery systems. As a reminder, trade-ups have a net zero impact on our install base as an existing system is removed from our installed base when the new trade-up system is sold. Lastly, the average selling price or ASP of a delivery system in the quarter was $23,543. With the impact of the enticing promotions associated with Syndeo's launch behind us, we expect to see sequential improvement in ASP for the balance of the year. As a reminder, we guided to a high single-digit blended ASP increase for 2022, incorporating both trade-up and the Syndeo rollout in the U.S. Moving to slide 17, we reported a GAAP gross margin of 69.2% or 72.3% on an adjusted basis. Gross margin came in above our expectations due to the incredible strong demand from providers for delivery systems, creating fixed cost leverage from higher sales volume. With the most enticing of our promotions having expired at the end of March and associated units shipped, we expect trade-up volume to moderate in the second half of the year. During the quarter, we delivered adjusted EBITDA of $12.6 million. For the balance of the year, we expect our adjusted EBITDA to ramp up significantly, consistent with historical seasonality as we see the pull-through from our first half marketing spend and capitalize on the global demand. As we have stated repeatedly, we reserve the right to continue reinvesting our upside as growth accelerates in order to set the business up for long-term success. These investments in our golden triangle of sales, marketing, and training, driving engagement, build loyalty, and expand our community, all of which are key ingredients to sustain long-term growth. I will turn to slide 18 to discuss our cost details. Selling and marketing expenses in the second quarter were $44.9 million compared to $26.2 million for the second quarter last year, primarily driven by increases in planned marketing programs, personnel-related expenses, and sales commissions associated with higher revenues. Breaking this down, selling and marketing increased to 43.3% of sales, up by 393 basis points compared to the second quarter of 2021 or down 495 basis points compared to the first quarter of 2022. The year-over-year percentage increase was driven by increased spend in marketing, investment in our training program, and personnel-related expenses, including commissions. The sequential decrease was primarily driven by Syndeo launch-related investments in the first quarter of 2022. Our G&A expense of $27.6 million increased from $26.3 million last quarter and includes approximately $2 million of one-time transaction costs and $1.1 million in litigation costs to vigorously protect our technology and pursue ongoing patent and trademark infringement cases. Touching on R&D, we invested $2.6 million in the second quarter compared to $3 million in the prior year, which reflects the wind down of Syndeo-related R&D consulting costs, partially offset by investments in data and technology personnel. I will now move to our balance sheet highlights on slide 19. We ended the quarter with $821 million in cash and cash equivalents. We remain well-positioned to execute on our hyper-growth initiatives while keeping strategic M&A opportunities actionable. We also continue to carry $750 million of 1.25% convertible notes on the balance sheet, which we opportunistically raised for M&A among other uses. Our revolving credit facilities remain undrawn. Finally, our current shares outstanding are approximately $151 million. Turning now to our full year outlook on slide 20; as Andrew detailed, we raised our guidance for net sales to a range of $340 million to $350 million, up from our previous guidance of $330 million to $340 million. The early success of Syndeo in the U.S. and continued strong demand from consumers worldwide are the drivers behind the raise. Moving to the right, we reaffirm our 2022 adjusted EBITDA guidance of $50 million. We have emphasized repeatedly that 2021 and 2022 are outsized investment years for the business. As Andrew already mentioned, a vast market opportunity and favorable dynamics support our investment to cement our leadership position in the rapidly growing Beauty Health category. We're working towards better profitability by the end of 2022 and to continue the momentum towards historical levels in 2023. In conclusion, we are proud of our performance in the first half of the year and pleased with the position we're in to achieve our goals as we enter the second half. We expect to see the typical sequential pickup in demand and are confident in our ability to generate returns on our investment spending as we capture the unpenetrated market opportunity ahead of us. We will now gladly take your questions.

First question comes from Margaret Kaczor of William Blair.

This is Maggie Boeye on for Margaret today. I just wanted to start with the adjusted EBITDA guide. So obviously, another quarter raising the revenue guide and then reiterating the adjusted EBITDA guide. I know you guys have said that you're continuing to reinvest in the business. So maybe can you talk about when you expect to get more leverage off of these investments, especially given the fact that you're rolling into a global launch at the beginning of 2023?

Thank you for joining the call this morning. Yeah, as we've previously stated, we're a young company with a large white space ahead of us. So we're in that hyper-growth mode. So with the Board, we've put in a business plan that we are successfully delivering against that balances growth with profitability. So in 2022, we're continuing to invest in the business to drive that growth and demand around the world. And I would also remind you that we're delivering $50 million EBITDA, which is a growth of over 50% more than last year. So I acknowledge it's important to grow EBITDA, and we're on track to do that. But look, we aren't just investing for growth here. We are building a moat around our business. And it's a little bit like Monopoly. You need to own the properties to collect the rent. And we do need to have as many providers with our systems around the world to collect the consumer recurring revenue. So 2022 is our final year of elevated investment, and we will then focus on driving EBITDA margins towards historical levels in 2023 and beyond.

Great. I wanted to ask about the Syndeo launch. You're about one quarter into the launch in the U.S. Can you discuss what you've observed in the field, the data insights you’ve gathered, and any thoughts on future improvements to software, algorithms, and updates?

No, thank you. As we said in the recorded notes, we’re really thrilled with the launch of Syndeo in the U.S., and it was co-invented with our providers in mind, and you saw their feedback on page 8 of the deck, which has been very consistent with what we’re hearing. I mean, it’s a leap forward in technology and some of the feedback we’re getting, which gives us confidence. So the global launch is – the data connectivity, the improvements in user interface, the touchscreen technology, the LightStim LED, etc., all really big leap forwards, which we’re getting really good feedback on. In terms of the data, yeah, we are gathering data. It’s obviously early days with the 2,000 Syndeo plus systems placed. We’re learning all the time. And we’d love to come back to the market at a later stage and really share some of those insights of what we’re getting. And of course, just like any IoT product, we’ll continue to improve the software and app experience as we learn and grow together with our business partners, but we are very excited to launch internationally in the early part of 2023.

Thank you. Our next question will come from Steph Wissink of Jefferies.

Thank you. I'm going to sneak two in because one is just a clarifying question. Liyuan, if you could just talk a little bit about your comments on the delivery system ASP. You do expect it to advance into that high single-digit range for the year. But is there anything we need to be aware of in terms of sequencing on the pricing, just coming off of the Syndeo launch? And then Andrew, my bigger picture question is for you related to marketing strategy. As you've come in and spent time in the business, any changes that you're making to the execution or activation of marketing? Anything you're learning from the Syndeo launch that has you tweaking or shifting some of your focus within marketing mediums or plans for the back half?

Thanks for joining the call. So I'll let Liyuan kick off, then I'll handle the second part of that question.

Thank you for the question. Yes. So in terms of the ASP, all along what we have mentioned is obviously giving the actual sticker price for Syndeo. As we roll out in the U.S., we're no longer selling other systems such as Elite. So as a result, all the new units should automatically have a higher ASP. What we've been really stating is the fact that given the amount of trade-ups, right, the most significant promotions ended in March, and we'll continue to sell trade-up, but we reserve the right to promote as we see appropriate as we test and learn going forward. So on a blended basis, you're going to continue to see sequential improvement in terms of the ASP for the second half of the year. So when we take the entire year, this is to try to reinforce the guidance from the beginning. We believe on a blended basis compared to last year, the ASPs to be increasing by high single digits.

Regarding the second part of your question, it has been six months since I took on this role. The first half of the year has been really exciting for me. We have learned a great deal, and as I've mentioned before, our primary opportunity for Hydrafacial is to enhance our brand awareness. Last quarter, I indicated that we tested our aided awareness at 9% and unaided awareness at 2%. We have positioned ourselves as a well-kept secret in beauty, especially given our impressive NPS score of 44, which continues to rise. We know the experience is exceptional; we just need to encourage more consumers to try it. Since I came on board, we've been refining our marketing strategy. We are implementing a pyramid approach to brand building, focusing on doctors, physicians, and key opinion leaders at the top. This is evident in our collaborations with individuals like Dr. Paul Nassif, which help us establish trust and credibility. We've also improved our digital marketing by refining our search and paid social strategies. Additionally, we've been collaborating closely with aestheticians and influencers to enhance our branding. If you’ve been following our initiatives, you would have noticed substantial improvements in the quality and quantity of our content from the in-house content factory we established, which produces excellent material daily. Our engaged community of aestheticians and providers, whom I refer to as the Hydrafacial nation, generates a lot of free earned media for us. Moreover, we've continued with on-the-ground activations through the GLOWvolution tour, which recently wrapped up a successful leg in the U.S. for the first time this year, and we also expanded to Europe. While we maintain these in-person events, the key shift has been to balance them with broad-reach digital marketing. This approach has resulted in record levels of digital search activity on Google this quarter and our highest earned media value metrics to date. It's an exciting time for us as we continue to learn and adapt based on the data we collect regarding ROA.

So Steph, the only thing I’ll add to that from an investment point of view, this is why we’re being very vocal about we invest upfront, right? So from a seasonality point of view, all the big events happened already in the first half of the year. So this is another reason why we feel really comfortable, especially given all the ROI where we’re going to land for the second half of the year.

Our next question will be from Oliver Chen, Cowen and Company.

Andrew and Liyuan, congrats on a great quarter. As we think ahead, your guidance includes that gradual reopening of China. I just would love your thoughts on controllable factors in that region and what you see happening? Also you mentioned supply chain and those considerations. That continues to be a pretty dynamic topic. I would love your thoughts on what you're seeing there and what's embedded in guidance? And then Andrew, longer term, marketing as a percentage of sales, there's a huge awareness opportunity. So what do you see happening to that line item in 2023 more broadly? I'm sure we'll get more details over time.

Thank you. So look, I will kick off, hand over to Liyuan and maybe finish off with the last question. As to China, Oliver, as we've discussed before, we had a gradual opening in China built into our guidance. That's where we obviously feel confident reiterating our commitment to our $50 million EBITDA, and we've raised our net revenue. In saying that, lockdowns, further lockdowns, etcetera, would be something we need to balance. Saying that we're just so thrilled with the results, which we have been seeing outside of China and outside of the lockdown cities within China across the APAC, especially in Australia. Liyuan and I just returned from an extended trip to APAC, excluding China. I think we just returned with such a huge optimism of the future, and we see what a large sort of untapped reservoir of growth this region is for our business in the future.

Yeah, absolutely. Oliver, just to reiterate Andrew's point, as you know, we are growing so fast, especially for APAC and EMEA, you really do have to invest ahead, right? Because we keep on talking about you have to hire the sales team, the marketing and training. You actually have to train them to get ready to continue with that growth. So from an investment point of view, it's always going to be ahead a bit. So I wanted to reiterate that point. And followed by that, we feel very strong in terms of the reception outside of the market. But as Andrew had mentioned, it's hard to predict. So we kind of build that into our guidance. In terms of supply chain, I would say twofold. One, we continue to buy ahead and really manage the cost under our own control. Two, we've been sharing with you with the network optimization play we've been having, not only setting up a 3PL in Europe, but also trying to figure out secondary manufacturing in China. You will see temporary cost burden as you have these multiple sources as you expand. But over time, this is where the accretion is going to come from. We kind of had alluded early on as well. This is why we see potential margin upside beginning in Q4, and that would really work towards the next year as well.

Oliver, and thank you. To your last point on the marketing; so historically, when this company was private, which was not so long ago, by the way, they spent less than 5% on marketing. I think last year, we finished at 10%; this year, we're tracking for 12%. And as for next year, I think, look, it will continue to review and look at that. This is a very different model to perhaps vast consumer beauty brands. It's not a very high media model. We invest through that important golden triangle of sales, marketing and education as a business driver. So as we scale, we'll be looking at the ROIs on our investment very carefully to ensure that we're balancing our need to drive awareness, but also ensuring that we're delivering continued levels of profitability. But I think also the way we're refining our plans, that balance now we have between on-ground events, which deliver high ROI, but they are expensive with more broader reach activity has really helped us. And a good example of this year is the U.S. We cut down from 10 stops on the GLOWvolution to five this year, but that should not be seen as a negative because one of the reasons we did that is that we've opened a network of education centers around the world. New York is a great example. We've refurbished others around the country. So if you have a fantastic experience center, and I think you've been to the one in New York, clearly, you don't need to bring the GLOWvolution tour. So that's why we cut down the investment on the tour and shifted that investment to broader reach digital marketing. So that's where we're winning.

Sounds very agile. Just one quick follow-up. An incoming question we get is about your dry powder. You have a lot of financial flexibility and thinking about M&A. How are you seeing that market evolve given the valuations? And on the Glow & Go, any tips on how we should think about modeling it? It looks like you've been making a lot of beta testing progress.

Sure. So in terms of M&A, we’ve been – we believe that M&A will be an important component of the future. We have a unique opportunity to build up The Beauty Health platform. However, since raising the capital last fall, we’ve been extremely disciplined and extremely prudent as we outlined in the remarks. And we have seen valuations come down and continue to come down. We’re actively looking, but we’re going to wait to find the right opportunity, which is best for the company and our shareholders. In the meantime, we’re laser-focused on delivering our commitments and obviously globalizing the successful launch of Syndeo. In terms of Glow & Go, look, we did a beta test with a limited range of consumers to get better. I mean we are convinced that ultimately, there is a long-term opportunity for a take-home device. But with all the learnings, which we’ve now had from Syndeo in terms of its beautiful connectedness, and it gives a great user experience. We want to take all the insights from the test and ensure what we launch in the future is new, better, and different. So I wouldn’t include in any model for the moment, and we will obviously update the market in the future. At the moment, of course, we’re laser-focused on really globalizing the Syndeo.

Our next question will be from Olivia Tong of Raymond James.

My question is a follow-up on brand support. I know we're in a period of fairly elevated activity due to the launch. But can you discuss the extent of spending for the rest of the year? Since you’ve maintained your EBITDA outlook, a maintenance of profit on higher sales would imply either increased spending or less leverage. Do you have plans to increase spending, or is this more about keeping resources available to seize opportunities?

Olivia. Yes, it's a great point. I mean what we're trying to say is a lot of these marketing expenditures are planned way ahead. This is why we've been emphasizing from a seasonality point of view, whatever we invest in Q1, Q2 really benefits for the rest of the year. So suffice to say there's always digital marketing planning and other types of marketing, but you wouldn't see the outsized marketing activation as you witnessed in Q1 and Q2.

To reinforce my point, Olivia, we are investing not only for growth but also to establish a competitive advantage for the business. It's similar to the Monopoly analogy; you need to own the properties to collect the rent. This is the reason for our investments in the first half, and we are securing that leverage in the second half as we continue rolling out Syndeo.

Great. And then what should we be thinking in terms of when this Syndeo launch begins to bear fruit in consumables? I know new customers are stocked on consumables when they purchase a new system. How long does that last? And when should we start to see that flow through there?

Hi Olivia. So if you think about what we had mentioned, given this is a new launch, we provided training kits, usually it’s two to three months’ worth of free consumables essentially for all the trade-up and the new system sales. And usually it depends on, as we mentioned previously, 12% of our customers actually buy trade-up systems. If you just sit back and look at the lag, usually, it’s between one to two quarters of lag before they really speed up. So our vintage is not really cut in a way based on the year. It’s really based on is that one system is a multi-system, how long they’ve owned it, what sphere of customer they are. So in that thing, there’s always a ramp-up when it comes to consumables, and we’re trying to track utilization accordingly.

Our next question will be from Korinne Wolfmeyer, Piper Sandler.

Congratulations on the quarter. I would like to discuss your perspective on the current inflationary effects on consumers. You've performed well in the first half of the year, and it seems that utilization is trending positively. As we move into the latter part of the year, how are you approaching utilization? Are you incorporating any caution in your guidance regarding the possibility that consumers may start to space out appointments or visit less frequently, or are you not noticing any signs of that at this time? I'm interested in hearing your thoughts on this.

Korinne, thanks for joining the call. We obviously sit on this fabulous intersection of wellness, aesthetics, beauty, and skin care. And as you know from other companies, which you follow, these categories are extremely resilient in periods of economic downturn. We speak to providers every day all over the world. We've seen absolutely no slowdown in appetite for our category, for Hydrafacial, and demand remains very strong. And historically, that's proven time and again to be the lipstick index or the strength of skin care or aesthetics during periods of recession, etcetera. When we look back at our own data when we were a private company for the Global Financial Crisis of '09, we still continue to grow because of twofold. First, consumers, just like they were lipstick continue to prioritize spending in items which make them feel good. I would say these still look good and feel healthy. We're all on Zoom more often these days, hybrid working. We're really benefiting from those tailwinds. So we're seeing that strength. Secondly, as we've talked before, really, the secret of our business model is Hydrafacial is a gateway service. So we're by far the lowest-cost product in a doctor's physician's office. So even the GFC, we saw a trade down of consumers come in, they perhaps not doing more invasive expensive surgeries or fillers, but they still want to invest in themselves to make them feel good, make them confident. And that's why we're benefiting and we're seeing no demand. And that's why we feel so confident after speaking to so many providers around the world about the second half and why we've raised our guidance and reconfirmed our EBITDA. So we're feeling very strong about the time ahead.

And Korinne, the only thing I’ll add, when we look at our guidance for the second half of the year, we take into consideration the COVID impact in China in addition to that, believe it or not, talking to folks even in the U.S., the only cancellation we would be hearing are related to COVID. So there’s still some resurgence here and there. So we kind of take that into consideration. But absolutely, we feel really good in terms of consumables.

Our next question will be from Jon Block of Stifel.

Liyuan Woo: Absolutely, hi, Jon. So you're right on, gross margin is definitely one of the area and as I emphasize, especially towards the last quarter of the year, right? Because we are still building that whole infrastructure and network optimization, you continue to kind of spend and scale for the future. But absolutely, in the meanwhile, we're searching for kind of the accretion side of the equation. So we feel very strong in terms of that sequential improvement when it comes to gross margin, which would contribute. And two, we provide the guidance taking into consideration of the current market environment. As we always say, if the market environment improves, especially in China and other markets and if we generate additional revenue, we will continue to invest back into the business, but we have pretty strong levers in terms of control for G&A. Think about it as almost a 50-50 split, roughly speaking, between fixed versus variable, and there are various levers we can pull when it comes to the variable side of the equation, especially when it comes to marketing, as we emphasize a lot of the heavy lifting has been done in the beginning of the year, we can certainly pull the lever there. And in terms of some of the other infrastructure build, the one-time items, some of them are coming to finish. So you will start to see some of the leverage points there as well. Perfect. Very helpful. And then second question admittedly somewhat unrelated. But Andrew, just any reason to think about the international ramp for Syndeo being different than what you've experienced here in the U.S., better or worse? I guess where I'm going with this is, the demand here in the U.S. was through the roof. So can you discount less or who cares, is this all about just getting the next-gen system in the providers' hands due to the downstream positive impacts on utilization, etcetera? But I would just love your thoughts as that might be around the corner in early '23.

Jon, thanks in great to speak to you. Well, you in part answered the question which you asked. Absolutely, I will say that there’s a really growing excitement outside of the U.S. about Syndeo. They’ve seen it at trade shows and events. They’ve seen all the coverage and feedback online from our partners. So there’s a big excitement. Clearly, a big part of our model is that we have a playbook, which is very successful in the U.S., which we look to roll out globally in the New Year. Of course, there’s nuances by market. What we do have, as you know, we’ve discussed before together, is global pricing, we like to control pricing internally. So we don’t have any – externally, so we don’t have any secondary market. So no, we feel very good about the plan and looking forward to rolling out in Q1 of ‘23.

Thank you. The next question will come from Mr. Allen Gong of JPMorgan.

I just had one question kind of jumping back to the top line. So relative to kind of where The Street was at heading into the print, it looks like you came in above by roughly $20 million on the top line, largely driven by your delivery system strength. But when I look at the guide, you only raised it by around $10 million on the top and bottom. So I guess, like how much of that is conservatism and what you're seeing in terms of trends so far in the third quarter? And how much of that could be maybe a little bit of pull forward, given it looks like you did have a little bit higher churn in the quarter relative to expectations?

Thanks, Allen. So in terms of the Q2, as we talked about before, we provided pretty deep promotions back in March, right? So that generated a lot of the sales of the trade-up. And at this point, we’re not being very promotional, right? So back to Jon’s point earlier, we’re really controlling the pricing. So in that vein, we will continue to sell trade-up, but you will see from a trend point of view, that should be moderate because we’re not really launching international to the earlier point until the beginning of next year. So Allen, with that said, we should be really seeing the momentum building based on the new sales and especially given what’s going on with the gradual opening in China, and it’s kind of hard to see, right, in terms of how the lockdown will continue to evolve. So in that vein, we’re being very thoughtful in terms of providing our guidance. And we reemphasize as we’re selling a lot of these new Syndeo’s and the trade-ups, we keep on giving free consumables as well. So we take all of that into consideration. And just like every other quarter, we emphasize, if we do sell more, obviously, we will continue to build the business and inform the market as we see—we have more clarity.

Thank you. The next question will be from Bruce Jackson of The Benchmark Company.

Some follow-up questions about Europe. It was very strong. I was wondering if you could tell us a little bit about how the end-user demand is holding up and how the second half of the year might unfold given that you've got the partnership with Innerskin. Could we see like similar levels or continued acceleration? And then I've got one follow-up.

Bruce, thanks for joining. Great to hear from you. We're extremely thrilled with the success in Europe, plus 56% for the quarter and really continued momentum in demand. I think there's a really case in point where we make about investing forward. We've really upgraded our marketing late last year and early in the year in Europe. You've seen us showing up if you follow us in the tradeshows, events, and influencer events; you can see that payback coming through, which really talks to our investment and then getting leverage later. We've seen demand continue to our momentum. So we feel very good about the second half. There's some activity in the plan. We have the GLOWvolution tour now, which we've extended to Europe for the first time, making its way around Europe and obviously, complemented by the Jennifer Lopez, JLo launch, which is a global launch from Q4, which will also help amplify. So we really feel good about the guidance we've given. Of course, if things accelerate and China opens up, we'll obviously upgrade now. But we're trying to balance now with some of the uncertainty we have in China and with our commitment to delivering our targets.

Bruce, just to add one point, just to remind everybody, we have no revenue concentration, right? So if you think about, we have over 20,000 systems out there, but our biggest customer is less than 3% of our revenue. So just to give you emphasize that we’re comfortably partnering and experimenting. But usually, it doesn't really necessarily move the needle. It's really in the long run as we see the fruition.

Okay. And then my follow-up is also related to Europe on the foreign currency impact. Is most of that foreign currency impact in Europe? And has that stabilized? And did you do any hedging or is that something that's just going to kind of flow through for the next couple of quarters? That's it for me.

Great question, Bruce. Yeah, we’re very mindful and thoughtful when it comes to currency management. We’re likely not going to go through a hedging program from an accounting treatment point of view because those are very complex, but we’re constantly working on operational hedging just to make sure we have enough currency purchases, both in APAC and in EMEA to make sure from a real cash, not necessarily unrealized in this point of view to preserve our right and manage our hedging and currency.

The next question will be from Kyle Rose with Canaccord Genuity.

So look, I just wanted to see if you could comment a little bit more. I realize today was early days, and it's only plus or minus 2,000 units, but just the overall interaction that you're seeing with respect to the connectivity of Syndeo relative to what you're seeing on the consumer-facing apps. I mean, are you able to drive some push marketing-type of initiatives there? And then secondarily, just following your social over the course of the last several months, we've seen a big focus maybe outside the face, including the decolletage, I think you're treating other body parts as well. So if you could just maybe unpack that a little bit for us and just help us understand where clinicians are starting to treat.

Thanks for joining the call and I'll start with the second part of your question, which you're absolutely right. And thanks for seeing that leap forward in content. It's been really intentional for us with the new team we created in our content factory. Look, I think what is the beauty of our system is that for a provider, an aesthetician, the revenue stream is just more about the pace. And I think I've been really intentional with the team since I joined that where there's so many bigger parts of the body, which we can utilize the service on, which bigger surface space means bigger consumables. So you're going to see big pushes behind back-based decolletage. HydraBeauty and legs have been a big thing this summer, if you've been following us. So that's really intentional. And we put training and protocols in place and who knows other boosters activity, which could be coming down the line in the future, which we'll come and talk about in a later stage. So very excited about that area. In terms of Syndeo and data connectivity, our first phase of this, as we talked last quarter, is really getting the systems out, and we've placed over those 2,000 Syndeo. With that learning, which we're getting in real-time from providers and that data, which we're beginning to collect, that's going to help us renew and re-launch the app to give a better user experience in the near future. And I will say at the moment, we'll look forward, I think, in a quarter or two, and sharing a lot more data of what we're learning. It's super interesting. The reason we're not sharing now, there's a lot of bias in it, you can imagine the first couple of thousand providers have bought it. Many of them are trade-ups. So they're super engaged with Syndeo. They're really active. They're posting as well. So that's obviously going to be a bias on the data. So let's just even out the kinks, and we'll come back and share some of the great and powerful learnings we're getting, which will help us really unlock future growth for our business in the future.

Great. And then if I can just squeak in one follow-up. It's just obviously, really strong demand for Syndeo. Just wondering if you're seeing any different market trends with respect to the interest in purchasing of the capital systems? Are you seeing it come from different geographies and/or different channels? Just wanted to see where the demand is coming from.

Good question. I think obviously, we've launched at this stage only in the U.S. only. And we've seen it come from everywhere. I mean, I think our largest providers all across the U.S., every state we had a look at actually before the call. It's very uniform. It's coming from everywhere the demand. So there's no one particular state or channel in particular. Everyone is growing. There's a huge amount of momentum. It's such a big leap forward in technology. There's nothing like it, anything really in the Spa and facial. It's not a facial. It's a Hydrafacial. So there's a lot of excitement everywhere.

Kyle, the only thing to emphasize is, we kind of talked about how attractive in terms of ROI to our customers, and we truly see that firsthand, right? With EMEA and APAC, there’s no slowdown in terms of buying the Elite System either. That’s why we feel very confident to really roll it out at the most optimal timing, which is the beginning of next year. So that was really great to see.

Thank you. Our next question will be from Linda Bolton-Weiser, D.A. Davidson.

I was curious about the retail partners you have, such as Sephora, Ulta, and Nordstrom. What are the usage levels of your systems among them? Have they returned to pre-pandemic levels? Are these systems operating at 50% of their pre-pandemic usage, or what are the current levels? Is the growth with these retail partners due to increased usage of the system, or are they actually starting to install more systems in their stores?

Linda, hi, and thanks for joining the call. Good to speak to you. Retailers, as you say, small but really rapidly growing. It’s an exciting moment for us. Obviously, we just announced today our partnership in Europe with Galeries Lafayette, which we’re super excited about to continue to expand our retail. And by the way, it’s not just retail. We’ve got partnerships with luxury hotels, gyms, which if you follow, you’ve seen really growing over the last quarter. I think what we will say about retailers, we don’t break out in detail is that certainly, if we speak for North America with our biggest presence in Europe, biggest presence is across Ulta, Nordstrom, and Sephora. I think we’ve seen it all open up this year. A number of these services – of course, were on hold for an extended time during COVID. And I think, of course, now with the opening, we’ve seen consumers come back in the store. They got fed up with home shopping or curbside pickup and they’re committing for experience. And of course, Hydrafacial is really the only skin care experience on the floor in so many of these retailers. So we have a real competitive advantage. So of course, they’re getting makeovers and getting blowouts of hair and we’re the skin service provider in this space. So we’re really excited about the growth opportunity ahead.

The next question will be from Amit Hazan of Goldman Sachs.

I'll limit it to just one. You previously indicated 3,500 to 4,000 systems annually. In '21, we sold over 6,000 systems, and this year, we're looking at 7,000, 8,000. Even on a net basis, we're still well above that 3,500 to 4,000 range. The question is, given the momentum in the business, is that still the right benchmark for us to consider as we approach Syndeo's international launch in '23 and '24?

Great question. I think the context we were giving when we were talking about the 3,500 to 4,000 is much more historical. As you recall, it’s a very U.S.-centric business, right? It was a 70-30 split. And as we continue to grow, we kind of have to take that into consideration. The way as a company, as we look at the trend, we are very much focused on new system sales as a trend, which we’ve been disclosing to you on a quarterly basis. And that’s kind of the base as we model out our business going forward.

Thank you. This concludes our question-and-answer session. I'd now like to turn the conference back over to Mr. Andrew Stanleick for closing remarks. Please go ahead. Thank you, operator. In closing, I will say, we are ecstatic about our results and are as confident as ever about the future of our business. Beauty Health exists in that bright space where beauty, aesthetics, wellness and health converge. This is a space post-COVID, which is growing rapidly and adding new devoted consumers by the day. The Beauty Health category has proven its resiliency time and time again, and our upper middle-class consumer who is generally less impacted by economic downturns reinforces the conviction we have in achieving our outlook. We remain committed to our 2022 strategy of investing in the business. The time to play offense is now, and we expect our investments this year in sales, marketing, and training to strengthen our community and propel future growth while still delivering an implied 2022 EBITDA growth of 53% year-over-year. And I'm eager to share more of our vision and detail about our long-term growth ambition during Investor Day on September 15, and I look forward to seeing many of you there. Thank you all again for joining us today. Goodbye. The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.